Results 151 to 160 of about 23,011 (205)

Enhancement of CAR-T cell efficacy and persistence via CD30 costimulation and NF-κB signaling. [PDF]

Mol Cancer
Su Y, Yang G, Chen B, Qian Y, Ma W, Jiang X, Yu Q, Li Y, Xu L.   +8 more
europepmc   +1 more source

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study. [PDF]

Blood Adv
Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet M, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, André M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas-Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens MC, Griolet S, Gaulard P, Delfau-Larue MH, de Leval L, Damaj GL.   +42 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CD30 in Cutaneous Pathology

The American Journal of Dermatopathology, 2023
Abstract: The discovery of CD30 as a diagnostic marker was essential in the identification of not only some lymphomas but also many other solid tumors and benign reactive conditions. Many CD30+ cutaneous disorders and tumors have been categorized since the identification of the marker.
Angel Fernandez-Flores, David Cassarino
openaire   +2 more sources

CD30 expression in seminoma

Human Pathology, 1996
In testicular germ cell tumors the CD30 antigen has been shown to be regularly expressed in embryonal carcinoma and was thus suggested as a marker for this particular neoplasm. Very recently, it has been proven that the monoclonal antibody Ber-H2 is suitable for the detection of this membrane antigen in paraffin sections.
A, Hittmair, H, Rogatsch, A, Hobisch, G, Mikuz, H, Feichtinger   +4 more
openaire   +2 more sources

CD30 ligand in lymphoma patients with CD30+ tumors.

Journal of Clinical Oncology, 1997
PURPOSE CD30 ligand (CD30L), which is expressed on resting B and activated T lymphocytes, can induce cell death in several CD30+ cell lines. Patients with CD30+ tumors (Hodgkin's disease and Ki-1+ non-Hodgkin's lymphoma) frequently have elevated soluble CD30 (sCD30) levels in their serum, which correlates with a poor prognosis.
A, Younes, U, Consoli, V, Snell, K, Clodi, K O, Kliche, J L, Palmer, H J, Gruss, R, Armitage, E K, Thomas, F, Cabanillas, M, Andreeff   +10 more
openaire   +2 more sources

CD30 Ligand/CD30 Interaction Is Involved in Pathogenesis of Inflammatory Bowel Disease

Digestive Diseases and Sciences, 2012
Although CD30 has long been recognized as an important marker in many lymphomas of diverse origin, and as an activation molecule on B and T cells, its primary function has remained obscure. Soluble CD30 (sCD30) is released from CD30 on the cell membrane by enzymatic cleavage.
Shinichi, Somada, Hiromi, Muta, Kazuhiko, Nakamura, Xun, Sun, Kuniomi, Honda, Eikichi, Ihara, Hirotada, Akiho, Ryoichi, Takayanagi, Yasunobu, Yoshikai, Eckhard R, Podack, Kenzaburo, Tani   +10 more
openaire   +2 more sources

CD30+ Neoplasms of the Skin

Current Hematologic Malignancy Reports, 2011
Cutaneous T-cell lymphomas (CTCLs) are subdivided by lesion morphology, behavior, and surface receptors. Mycosis fungoides (MF) and Sézary syndrome (SS) are derived from CD4+ effector or central memory T-cells respectively. MF presents clinically as patches, plaques, or tumors, and SS presents with erythroderma.
openaire   +2 more sources